decadron
PHARMACY

Fera Pharma to market Pragma’s Decadron

BY DSN STAFF

Fera Pharmaceuticals will be handling sales and marketing for the planned launch of Pragma Pharmaceuticals’ Decadron tablets. Pragma said that it anticipated an early 2018 launch date of the dexamethasone tablets.

Decadron will be available in 0.5-, 0.75-, 4- and 6-mg dosage strength tablets. The drug is a steroid that the companies said is widely used for its effectiveness and potency.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin intros generic Namenda XR

BY David Salazar

Lupin has launched its generic of Namenda XR (memantine hydrochloride extended release) capsules. The drug is indicated to treat moderate-to-severe dementia of the Alzheimer’s type.

Lupin’s generic Namenda XR will be available in 7-, 14-, 21- and 28-mg dosage strengths. The product had U.S. sales of roughly $936 million for the 12 months ended December 2017, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
new drug
PHARMACY

FDA approves Lupin’s generic Tamiflu for oral suspension

BY David Salazar

The Food and Drug Administration has approved Lupin’s generic Tamiflu for oral suspension (oseltamivir phosphate for oral suspension, 6 mg/ml). Lupin said it would shortly begin promoting the product.

Lupin’s generic Tamiflu for oral suspension is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients ages 1 year and older.

The product had U.S. sales of roughly $358 million for the 12 months ended October 2017, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?